Pricing Log in Create free account

Kalaris Therapeutics Inc. (KLRS) vs Verrica Pharmaceuticals Inc. (VRCA)

Kalaris Therapeutics Inc. and Verrica Pharmaceuticals Inc. are both Biotechnology companies. Kalaris Therapeutics Inc. and Verrica Pharmaceuticals Inc. are of similar size ($53.1M and $51.6M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −102.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Kalaris Therapeutics Inc. leads on 9 and Verrica Pharmaceuticals Inc. on 4.

Valuation

Metric KLRS VRCA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 2.26 9.40
P/B 1.01 15.93 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.33 n/m 0.66
EV/Sales n/m 2.33 9.02
Earnings yield (85.64%) (51.86%) (32.88%)
Free cash flow yield (70.40%) (19.81%) (23.13%)

Profitability

Metric KLRS VRCA Biotechnology median
Gross margin 0.00% 85.89% 68.51%
Operating margin 0.00% (93.59%) 0.00%
Net margin 0.00% (102.84%) 0.00%
Free cash flow margin 0.00% (44.02%) 0.00%
Return on equity (79.91%) 473.29% (51.96%)
Return on assets (46.02%) (83.02%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KLRS VRCA Biotechnology median
Revenue growth (TTM) — 106.21% 6.76%
EPS growth (last fiscal year) 94.50% 88.65% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KLRS VRCA Biotechnology median
Debt to equity 0.00 0.18 0.00
Current ratio 10.98 1.45 4.97
Net debt to EBITDA 2.54 2.59 1.01

Dividend

Metric KLRS VRCA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KLRS VRCA Biotechnology median
Market cap 51.55m 53.08m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack